Juvenile idiopathic arthritis-associated uveitis. Clarke S.L.N., Sen E.S., & Ramanan A.V. 2016.
Juvenile idiopathic arthritis-associated uveitis [link]Paper  abstract   bibtex   
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood, with JIA-associated uveitis its most common extra-articular manifestation. JIA-associated uveitis is a potentially sight-threatening condition and thus carries a considerable risk of morbidity. The aetiology of the condition is autoimmune in nature with the predominant involvement of CD4+ T cells. However, the underlying pathogenic mechanisms remain unclear, particularly regarding interplay between genetic and environmental factors. JIA-associated uveitis comes in several forms, but the most common presentation is of the chronic anterior uveitis type. This condition is usually asymptomatic and thus screening for JIA-associated uveitis in at-risk patients is paramount. Early detection and treatment aims to stop inflammation and prevent the development of complications leading to visual loss, which can occur due to both active disease and burden of disease treatment. Visually disabling complications of JIA-associated uveitis include cataracts, glaucoma, band keratopathy and macular oedema. There is a growing body of evidence for the early introduction of systemic immunosuppressive therapies in order to reduce topical and systemic glucocorticoid use. This includes more traditional treatments, such as methotrexate, as well as newer biological therapies. This review highlights the epidemiology of JIA-associated uveitis, the underlying pathogenesis and how affected patients may present. The current guidelines and criteria for screening, diagnosis and monitoring are discussed along with approaches to management. Copyright © 2016 Clarke et al.
@misc{clarke_s.l.n._juvenile_2016,
	title = {Juvenile idiopathic arthritis-associated uveitis},
	url = {http://www.ped-rheum.com/},
	abstract = {Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood, with JIA-associated uveitis its most common extra-articular manifestation. JIA-associated uveitis is a potentially sight-threatening condition and thus carries a considerable risk of morbidity. The aetiology of the condition is autoimmune in nature with the predominant involvement of CD4+ T cells. However, the underlying pathogenic mechanisms remain unclear, particularly regarding interplay between genetic and environmental factors. JIA-associated uveitis comes in several forms, but the most common presentation is of the chronic anterior uveitis type. This condition is usually asymptomatic and thus screening for JIA-associated uveitis in at-risk patients is paramount. Early detection and treatment aims to stop inflammation and prevent the development of complications leading to visual loss, which can occur due to both active disease and burden of disease treatment. Visually disabling complications of JIA-associated uveitis include cataracts, glaucoma, band keratopathy and macular oedema. There is a growing body of evidence for the early introduction of systemic immunosuppressive therapies in order to reduce topical and systemic glucocorticoid use. This includes more traditional treatments, such as methotrexate, as well as newer biological therapies. This review highlights the epidemiology of JIA-associated uveitis, the underlying pathogenesis and how affected patients may present. The current guidelines and criteria for screening, diagnosis and monitoring are discussed along with approaches to management. Copyright © 2016 Clarke et al.},
	journal = {Pediatric Rheumatology},
	author = {{Clarke S.L.N.} and {Sen E.S.} and {Ramanan A.V.}},
	year = {2016},
	keywords = {*juvenile rheumatoid arthritis, *juvenile rheumatoid arthritis/di [Diagnosis], *juvenile rheumatoid arthritis/dt [Drug Therapy], *juvenile rheumatoid arthritis/ep [Epidemiology], *juvenile rheumatoid arthritis/et [Etiology], *uveitis/di [Diagnosis], *uveitis/dt [Drug Therapy], *uveitis/ep [Epidemiology], *uveitis/et [Etiology], CD4 T lymphocyte, CD4 antigen/ec [Endogenous Compound], CD8 antigen/ec [Endogenous Compound], CD8+T lymphocyte, Child, HLA B27 antigen/ec [Endogenous Compound], HLA DPB1 antigen/ec [Endogenous Compound], HLA DR1 antigen/ec [Endogenous Compound], HLA DR5 antigen/ec [Endogenous Compound], HLA DRB1 antigen/ec [Endogenous Compound], abatacept/ct [Clinical Trial], abatacept/dt [Drug Therapy], adalimumab/ae [Adverse Drug Reaction], adalimumab/cm [Drug Comparison], adalimumab/ct [Clinical Trial], adalimumab/dt [Drug Therapy], azathioprine/ae [Adverse Drug Reaction], azathioprine/dt [Drug Therapy], biological product/ct [Clinical Trial], biological product/dt [Drug Therapy], blindness, bone marrow suppression/si [Side Effect], cataract, cataract/co [Complication], cataract/si [Side Effect], cataract/su [Surgery], childhood, clinical feature, clinical study, corticosteroid/ae [Adverse Drug Reaction], corticosteroid/dt [Drug Therapy], cyclopentolate/dt [Drug Therapy], cycloplegic agent/dt [Drug Therapy], cyclosporin A/ae [Adverse Drug Reaction], cyclosporin A/dt [Drug Therapy], dexamethasone sodium phosphate/dt [Drug Therapy], diagnosis, disease association, drug substitution, drug withdrawal, environmental factor, etanercept/cm [Drug Comparison], etanercept/ct [Clinical Trial], etanercept/dt [Drug Therapy], ethnicity, eye pain, eye redness, gastrointestinal symptom/si [Side Effect], glaucoma, glaucoma/co [Complication], glaucoma/su [Surgery], glucocorticoid, glucocorticoid/ae [Adverse Drug Reaction], glucocorticoid/dt [Drug Therapy], groups by age, hair loss/si [Side Effect], headache, hematologic disease/si [Side Effect], human, hypertension/si [Side Effect], immunosuppressive agent/dt [Drug Therapy], immunosuppressive treatment, incidence, infection/si [Side Effect], infliximab/cm [Drug Comparison], infliximab/ct [Clinical Trial], infliximab/dt [Drug Therapy], iridocyclitis, juvenile rheumatoid arthritis/dt [Drug Therapy], keratopathy, kidney dysfunction/si [Side Effect], leflunomide/cm [Drug Comparison], leflunomide/dt [Drug Therapy], leukopenia/si [Side Effect], lipodystrophy/si [Side Effect], liver dysfunction/si [Side Effect], liver enzyme/ec [Endogenous Compound], macular edema, meta analysis (topic), methotrexate, methotrexate/ae [Adverse Drug Reaction], methotrexate/cb [Drug Combination], methotrexate/cm [Drug Comparison], methotrexate/ct [Clinical Trial], methotrexate/dt [Drug Therapy], methylprednisolone/dt [Drug Therapy], monitoring, morbidity, mycophenolate mofetil/ae [Adverse Drug Reaction], mycophenolate mofetil/cb [Drug Combination], mycophenolate mofetil/dt [Drug Therapy], nausea/si [Side Effect], pathogenesis, patient monitoring, phacoemulsification, photophobia, placebo, practice guideline, prednisolone acetate/dt [Drug Therapy], prevalence, prevention, priority journal, prognosis, randomized controlled trial (topic), review, risk assessment, screening, screening test, sex difference, systematic review (topic), tacrolimus/ae [Adverse Drug Reaction], tacrolimus/dt [Drug Therapy], topical drug administration, trabeculectomy, treatment failure, tropicamide/dt [Drug Therapy], unindexed drug, unspecified side effect/si [Side Effect], uveitis/dt [Drug Therapy]}
}

Downloads: 0